Streptozotocin-associated lymphopenia in cynomolgus monkeys

Islets

Volumn 6, Issue 3, 2014, Pages

  Nagaraju, Santosh ^a   Bertera, Suzanne ^b   Funair, Amber ^b   Wijkstrom, Martin ^a   Trucco, Massimo ^b   Cooper, David K C ^a   Bottino, Rita ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

Author keywords

Cynomolgus; Diabetes; Islets; Lymphopenia; Monkey; Monocytes; Pig; Streptozotocin

Indexed keywords

HEMOGLOBIN A1C; MONOCYTE CHEMOTACTIC PROTEIN 1; STREPTOZOCIN; GLYCOSYLATED HEMOGLOBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD CELL COUNT; CONTROLLED STUDY; DISEASE ASSOCIATION; HYPERGLYCEMIA; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MACACA FASCICULARIS; MONOCYTE; NONHUMAN; OBSERVATIONAL STUDY; PANCREAS ISLET TRANSPLANTATION; PANCREAS TRANSPLANTATION; PROTEIN BLOOD LEVEL; ANIMAL; BLOOD; CHEMICALLY INDUCED; EXPERIMENTAL DIABETES MELLITUS; GLUCOSE TOLERANCE TEST;

ANIMALS; CHEMOKINE CCL2; DIABETES MELLITUS, EXPERIMENTAL; GLUCOSE TOLERANCE TEST; HEMOGLOBIN A, GLYCOSYLATED; LYMPHOCYTE COUNT; LYMPHOPENIA; MACACA FASCICULARIS; STREPTOZOCIN;

EID: 84914689496     PISSN: 19382014     EISSN: 19382022     Source Type: Journal    
DOI: 10.4161/19382014.2014.944441     Document Type: Article

References (31)

1. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008; 51:216-26; PMID: 18087688; http://dx.doi.org/10.1007/s00125-007-0886-7
2. Broder LE, Carter SK. Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med 1973; 79:108-18; PMID: 4352784; http://dx.doi.org/10.7326/0003-4819-79-1-108
3. Murray-Lyon IM, Eddleston AL, Williams R, Brown M, Hogbin BM, Bennett A, Edwards JC, Taylor KW. Treatment of multiple-hormone-producing malignant islet-cell tumour with streptozotocin. Lancet 1968; 292:895-8; http://dx.doi.org/10.1016/S0140-6736(68)91058-1
4. Schein P, Kahn R, Gorden P, Wells S, Devita VT. Streptozotocin for malignant insulinomas and carcinoid tumor: report of 8 cases and review of the literature. Arch Intern Med. 1973; 132:555-61; PMID: 4355081; http://dx.doi.org/10.1001/archinte.1973.03650100069013
5. Moertel CG, Reitemeier RJ, Schutt AJ, Hahn RG. Phase II study of streptozotocin (NSC-85998) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 1971; 55:303-7; PMID: 5115851
6. Szkudelski T. The mechanism of alloxan and streptozotocin action in b-cells of the rat pancreas. Physiol Res. 2001; 50:537-46; PMID: 11829314
7. Dufrane D, van Steenberghe M, Guiot Y, Goebbels RM, Saliez A, Gianello P. Streptozotocin-induced diabetes in large animals (pigs/primates): role of GLUT2 transporter and beta-cell plasticity. Transplantation 2006; 81:36-45; PMID: 16421474; http://dx.doi.org/10.1097/01.tp.0000189712.74495.82
8. Graham ML, Janecek JL, Kittredge JA, Hering BJ, Schuurman HJ. The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources. Comp Med. 2011; 61:356-60; PMID: 22330251
9. Rood PP, Bottino R, Balamurugan AN, Smetanka C, Ezzelarab M, Busch J, Hara H, Trucco M, Cooper DK. Induction of diabetes in cynomolgus monkeys with high-dose streptozotocin - adverse effects and early responses. Pancreas 2006; 33:287-92; PMID: 17003651; http://dx.doi.org/10.1097/01.mpa.0000235307.04110.a2
10. Koulmanda M, Qipo A, Chebrolu S, O'Neil J, Auchincloss H, Smith RN. The effect of low versus high dose of streptozotocin in cynomolgus monkeys (Macaca fascilularis). Am J Transplant 2003; 3:267-72; PMID: 12614280; http://dx.doi.org/10.1034/j.1600-6143.2003.00040.x
11. Graham ML, Mutch LA, Kittredge JA, Rieke EF, Robinson NA, Zolondek EK, Faig AW, Dufour TA, Munson JW, Schuurman HJ. Management of adverse side-effects after chemotherapy in macaques as exemplified by streptozotocin: case studies and recommendations. Lab Anim 2012; 46:178-92; PMID: 22577153; http://dx.doi.org/10.1258/la.2012.011077
12. Wu D, Zou C, Yue F, Li X, Li S, Zhang YA. The effect of long-term streptozotocin-induced diabetes mellitus (STZ-DM) on cynomolgus (Macaca Fascicularis) monkeys. J Med Primatol 2009; 38:15-22; PMID: 19018946; http://dx.doi.org/10.1111/j.1600-0684.2008.00300.x
13. Nichols WK, Spellman JB, Vann LL, Daynes RA. Immune responses of diabetic animals: direct immunosuppressant effects of streptozotocin in mice. Diabetologia 1979; 16:51-7; PMID: 153868; http://dx.doi.org/10.1007/BF00423151
14. Takayama Y, Ichikawa T, Maki T. Effect of STZ administration on islet isograft and allograft survival in NOD mice. Diabetes 1993; 42:324-9; PMID: 8425668; http://dx.doi.org/10.2337/diab.42.2.324
15. Koulmanda M, Qipo A, Auchincloss HJ Jr, Smith RN. Effects of streptozotocin on autoimmune diabetes in NOD mice. Clin Exp Immunol 2003; 134:210-6; PMID: 14616779; http://dx.doi.org/10.1046/j.1365-2249.2003.02293.x
16. Muller YD, Golshayan D, Ehirchiou D, Wyss JC, Giovannoni L, Meier R, Serre-Beinier V, Puga Yung G, Morel P, et al. Immunosuppressive effects of streptozotocin-induced diabetes result in absolute lymphopenia and a relative increase of T regulatory cells. Diabetes 2011; 60:2331-40; PMID: 21752956; http://dx.doi.org/10.2337/db11-0159
17. Nichols WK, Vann LL, Spellman JB. Streptozotocin effects on T lymphocytes and bone marrow cells. Clin Exp Immunol 1981; 46:627-32; PMID: 6461461
18. Levine BS, Henry MC, Port CD, Rosen E. Toxicologic evaluation of streptozotocin (NSC 85998) in mice, dogs and monkeys. Drug Chem Toxicol 1980; 3:201-12; PMID: 6452996; http://dx.doi.org/10.3109/01480548009108283
19. Sennels HP, Jørgensen HL, Hansen AL, Goetze JP, Fahrenkrug J. Diurnal variation of hematology parameters in healthy young males: the Bispebjerg study of diurnal variations. Scand J Clin Lab Invest 2011; 71:532-41; PMID: 21988588; http://dx.doi.org/10.3109/00365513.2011.602422
20. Marigliano M, Casu A, Bertera S, Trucco M, Bottino R. Hemoglobin A1c percentage in nonhuman primates: a useful tool to monitor diabetes before and after porcine pancreatic islet xenotransplantation. J Transplant 2011; 965605; http://dx.doi.org/10.1155/2011/965605
21. Weiss RB. Streptozocin: a review of its pharmacology, efficacy, and toxicity. Cancer Treat Rep 1982; 66:427-38; PMID: 6277485
22. Rakieten N, Rakieten Ml, Nadkarni MV. Studies on the diabetogenic action of streptozotocin (NSC-37917). Cancer Chemother Rep 1968; 29:91-8.
23. Schnedl WJ, Ferber S, Johnson JH, Newgard CB. STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes 1994; 43:1326-33; PMID: 7926307; http://dx.doi.org/10.2337/diab.43.11.1326
24. Paik SG, Fleischer N, Shin SI. Insulin-dependent diabetes mellitus induced by subdiabetogenic doses of streptozotocin: obligatory role of cell-mediated autoimmune processes. Proc Natl Acad Sci USA 1980; 77:6129-33; http://dx.doi.org/10.1073/pnas.77.10.6129
25. Luo B, Chan WF, Lord SJ, Nanji SA, Rajotte RV, Shapiro AMJ, Anderson CC. Diabetes induces rapid suppression of adaptive immunity followed by homeostatic T-cell proliferation. Scand J Immunol 2007; 65:22-31; PMID: 17212763; http://dx.doi.org/10.1111/j.1365-3083.2006.01863.x
26. Ishibashi T, Kitahara Y, Harada Y, Harada S, Takamoto M, Ishibashi T. Immunologic features of mice with streptozotocin-induced diabetes: depression of their immune responses to sheep red blood cells. Diabetes 1980; 29:516-23; PMID: 7380115; http://dx.doi.org/10.2337/diab.29.7.516
27. Wellhausen SR. Definition of streptozocin toxicity for primary lymphoidal tissues. Diabetes 1986; 35:1404-11; PMID: 2945746; http://dx.doi.org/10.2337/diab.35.12.1404
28. Deeds MC, Anderson JM, Armstrong AS, Gastineau DA, Hiddinga HJ, Jahangir A, Eberhardt NL, Kudva YC. Single dose streptozotocin induced diabetes: considerations for study design in islet transplantation models. Lab Anim 2011; 45:131-40; PMID: 21478271; http://dx.doi.org/10.1258/la.2010.010090
29. Lee I, Wang L, Wells AD, Ye Q, Han R, Dorf ME, Kuziel WA, Rollins BJ, Chen L, Hancock WW. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003; 171:6929-35; PMID: 14662900; http://dx.doi.org/10.4049/jimmunol.171.12.6929
30. Ehrnfelt C, Kumagai-Braesch M, Uzunel M, Holgersson J. Adult porcine islets produce MCP-1 and recruit human monocytes in vitro. Xenotransplantation 2004; 11:184-94; PMID: 14962280; http://dx.doi.org/10.1046/j.1399-3089.2003.00104.x
31. Piemonti L, Leone BE, Nano R, Saccani A, Monti P, Maffi P, Bianchi G, Sica A, Peri G, Melzi R, et al. Human pancreatic islets produce and secrete MCP-1/CCL2: relevance in human islet transplantation. Diabetes 2002; 51:55-65; PMID: 11756323; http://dx.doi.org/10.2337/diabetes.51.1.55